Managing psychiatric comorbidity within versus outside of methadone treatment settings: A randomized and controlled evaluation

Addiction

Volumn 108, Issue 11, 2013, Pages 1942-1951

  Brooner, Robert K ^a   Kidorf, Michael S ^a   King, Van L ^a   Peirce, Jessica ^a   Neufeld, Karin ^a   Stoller, Ken ^a   Kolodner, Ken ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug use; Integrated care; Methadone maintenance; Psychiatric care; Psychiatric comorbidity; Treatment response

Indexed keywords

METHADONE; NARCOTIC AGENT;

ADULT; AMBULATORY CARE; COMORBIDITY; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; FEMALE; HOSPITAL PATIENT; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MALE; MENTAL DISORDERS; OPIOID-RELATED DISORDERS; ORGANIZATION AND MANAGEMENT; OUTPATIENT; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; ARTICLE; CONTROLLED CLINICAL TRIAL; DRUG USE; INTEGRATED CARE; MENTAL DISEASE; MENTAL HEALTH CARE; METHADONE TREATMENT; METHODOLOGY; OPIATE ADDICTION; PSYCHIATRIC COMORBIDITY; PSYCHOLOGICAL ASPECT; TREATMENT RESPONSE;

ADULT; AMBULATORY CARE; BALTIMORE; COMORBIDITY; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HUMANS; INPATIENTS; MALE; MENTAL DISORDERS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; OUTPATIENTS; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME;

DRUG USE; INTEGRATED CARE; METHADONE MAINTENANCE; PSYCHIATRIC CARE; PSYCHIATRIC COMORBIDITY; TREATMENT RESPONSE;

EID: 84885395755     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12269     Document Type: Article

References (40)

1. Gowing L., Farrell M. F., Bornemann R., Sullivan L. E., Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; (8): CD004145.
2. McLellan A. T., Lewis D. C., O'Brien C. P., Kleber H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-1695.
3. Brooner R. K., King V. L., Kidorf M., Schmidt C. W., Bigelow G. E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54: 71-80.
4. McGovern M. P., Xie H., Segal S. R., Siembab L., Drake R. E. Addiction treatment services and co-occurring disorders. J Subst Abuse Treat 2006; 31: 267-275.
5. Bohnert A. S., Ilgen M. A., Ignacio R. V., McCarthy J. F., Valenstein M., Blow F. C. Risk of death from accidental overdose associated with psychiatric and substance use disorders. Am J Psychiatry 2012; 169: 64-70.
6. Cacciola J. S., Alterman A. I., Rutherford M. J., McKay J. R., Mulvaney F. D. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 2001; 61: 271-280.
7. Carpentier P. J., Krebbe P. F., van Gogh M. T., Knapen L. J., Buitelaar J. K., de Jong C. A. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict 2009; 18: 470-480.
8. Compton W. M., Cottler L. B., Jacobs J. L., Ben-Abdallah A., Spitznagel E. L. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry 2003; 160: 890-895.
9. Rounsaville B. J., Weissmann M. M., Crits-Christoph K., Wilber H., Kleber H. D. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psychiatry 1982; 39: 151-156.
10. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patient with Major Depressive Disorder, 3rd edn. Arlington, VA: American Psychiatric Association; 2010, 152 p.
11. Nunes E. V., Levin F. R. Treatment of depression in patients with alcohol or other drug dependence. JAMA 2004; 291: 1887-1896.
12. Pedrelli P., Iovieno N., Vitali M., Tedeschini E., Bentley K. H., Papakostas G. I. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol 2011; 31: 582-586.
13. Pringle J. L., Emptage N. P., Hubbard R. L. Unmet needs for comprehensive services in outpatient addiction treatment. J Subst Abuse Treat 2006; 30: 183-189.
14. Kidorf M., King V. L., Brooner R. K. Counseling and psychosocial services. In: Strain E. C., Stitzer M. L., editors. The Treatment of Opioid Dependence. Baltimore, MD: Johns Hopkins University Press; 2006, p. 119-150.
15. Sacks S., Chandler R., Gonzales J. Responding to the challenge of co-occurring disorders: suggestions for future research. J Subst Abuse Treat 2008; 34: 139-146.
16. Killaspy H., Banerjee S., King M., Lloyd M. Prospective controlled study of psychiatric out-patient non-attendance. Br J Psychiatry 2000; 176: 160-165.
17. Lydecker K. P., Tate S. R., Cummins K. M., McQuaid J., Granholm E., Brown S. A. Clinical outcomes of an integrated treatment for depression and substance use disorders. Psychol Addict Behav 2010; 24: 453-465.
18. Stein M. D., Solomon D. A., Herman D. S., Anthony J. L., Ramsey S. E., Anderson B. J. etal. Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users. Arch Gen Psychiatry 2004; 61: 152-159.
19. Donald M., Dower J., Kavanagh D. Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomized controlled trials. Soc Sci Med 2005; 60: 1371-1383.
20. Drake R. E., O'Neal E. L., Wallach M. A. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat 2008; 34: 123-138.
21. Mueser K. T., Glynn S. M., Cather C., Xie H., Zarate R., Smith L. F. etal. A randomized controlled trial of family intervention for co-occurring substance use and severe psychiatric disorders. Schizophr Bull 2013; 3: 658-672.
22. Brooner R. K., Kidorf M. Using behavioral reinforcement to improve methadone treatment participation. Sci Pract Perspect 2002; 1: 38-48.
23. First M. B., Spitzer R. L., Gibbon M., Williams J. B. W. Structured Clinical Interview for DSM-IV Axis Disorders-Patient Edition (SCID-I/P, version 2.0). New York: New York State Psychiatric Institute; 1995.
24. Derogatis L. R. SCL-90-R. Administration, Scoring, and Procedures Manual II, 2nd edn. Baltimore, MD: Clinical Psychometric Research; 1983.
25. Derogatis L. R., Cleary P. Confirmation of the dimensional structure of the SCL-90: a study in construct validation. J Clin Psychol 1977; 33: 981-989.
26. Morisky D. E., Green L. W., Levine D. M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
27. Kidorf M., Disney E. R., King V. L., Neufeld K., Beilenson P. L., Brooner R. K. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend 2004; 74: 115-122.
28. Center for Substance Abuse Treatment. Substance abuse treatment for persons with co-occurring disorders. Substance Abuse and Mental Health Services Administration (SAMHSA) (US), Treatment Improvement Protocol (TIP) Series. Rockville, MD: SAMHSA; 2005.
29. Brooner R. K., Kidorf M. S., King V. L., Stoller K. B., Peirce J. M., Bigelow G. E. etal. Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat 2004; 27: 223-232.
30. Brooner R. K., Kidorf M. S., King V. L., Stoller K. B., Neufeld K., Kolodner K. Comparing adaptive stepped care and monetary voucher interventions in the treatment of opioid dependent outpatients. Drug Alcohol Depend 2007; 88S: S14-23.
31. Singer J. D., Willett J. B. Modeling the days of our lives: using survival analysis when designing and analyzing longitudinal studies of duration and the timing of events. Psychol Bull 1991; 110: 268-290.
32. Bellack A. S., Bennett M. E., Gearon J. S., Brown C. H., Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006; 63: 426-432.
33. Helmus T. C., Saules K. K., Schoener E. P., Roll J. M. Reinforcement of counseling attendance and alcohol abstinence in a community-based dual-diagnosis treatment program: a feasibility study. Psychol Addict Behav 2003; 17: 249-251.
34. Sorensen J. L., Haug N. A., Delucchi K. L., Gruber V., Kletter E., Batki S. L. etal. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend 2007; 88: 54-63.
35. Carpenter K. M., Brooks A. C., Vosburg S. K., Nunes E. V. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend 2004; 74: 123-134.
36. Nunes E. V., Quitkin F. M., Donovan S. J., Deliyannides D., Ocepek-Welikson K., Koenig T. etal. Imipramine treatment of opiate-dependent patients with depressive disorders. Arch Gen Psychiatry 1998; 55: 153-160.
37. Petrakis I., Carroll K. M., Nich C., Gordon L., Kosten T., Rounsaville B. Fluoxetine treatment of depressive disorders in methadone maintained opioid addicts. Drug Alcohol Depend 1998; 50: 221-226.
38. Pampallona S., Bollini P., Tibaldi G., Kupelnick B., Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61: 714-719.
39. Beaulieu S., Saury S., Sareen J., Tremblay J., Schütz C. G., McIntyre R. S. etal. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patient with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry 2012; 24: 38-55.
40. Farre M., Mas A., Torrens M., Moreno V., Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002; 65: 283-290.